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AbstrAct
Introduction Interleukin-6 (IL-6) may be involved in 
ischaemia-reperfusion injury and myocardial remodelling 
after myocardial infarction (MI). We have recently shown 
that IL-6 inhibition by tocilizumab attenuates systemic 
inflammation and troponin T-release in patients with 
acute non-ST elevation MI (NSTEMI). Experimental 
studies suggest that IL-6 inhibition can limit infarct size 
through anti-inflammatory mechanisms, but this has 
not been tested in clinical studies. With the ASSessing 
the effect of Anti-IL-6 treatment in MI (ASSAIL-MI) trial, 
we aim to examine whether a single administration of 
the IL-6 receptor antagonist tocilizumab can increase 
myocardial salvage in patients with acute ST-elevation 
MI (STEMI).
Methods and analysis The ASSAIL-MI trial is a 
randomised, double blind, placebo-controlled trial, 
conducted at three high-volume percutaneous coronary 
intervention (PCI) centres in Norway. 200 patients with 
first-time STEMI presenting within 6 hours of the onset 
of chest pain will be randomised to receive tocilizumab 
or matching placebo prior to PCI. The patients are 
followed-up for 6 months. The primary endpoint is the 
myocardial salvage index measured by cardiac MRI (CMR) 
3–7 days after the intervention. Secondary endpoints 
include final infarct size measured by CMR and plasma 
markers of myocardial necrosis. Efficacy and safety 
assessments during follow-up include blood sampling, 
echocardiography and CMR.
Ethics and dissemination Based on previous experience 
the study is considered feasible and safe. If tocilizumab 
increases myocardial salvage, further endpoint-driven 
multicentre trials may be initiated. The ASSAIL-MI trial has 
the potential to change clinical practice in patients with 
STEMI.
Registration  Clinicaltrials. gov, identifier NCT03004703.
IntRoduCtIon
Myocardial infarction (MI) is a major cause of 
morbidity and mortality in the Western world.1 2 
Infarct size is the main determinant of death and 
complications after MI. Limiting the extent 
of the myocardial necrosis has therefore been 
an important objective. In patients presenting 
with acute ST segment elevation MI (STEMI), 
urgent myocardial reperfusion with percuta-
neous coronary intervention (PCI) is the most 
effective treatment to this end. However, the 
morbidity and mortality in patients with STEMI 
remain substantial.1 2 Other adjuvant strategies 
are therefore required to reduce infarct size 
Key questions
What is already known about this subject?
 ► Interleukin-6 (IL-6) may be involved in isch-
aemia-reperfusion injury and myocardial remod-
elling after myocardial infarction. Experimental 
studies suggest that IL-6 inhibition can limit infarct 
size through anti-inflammatory mechanisms.
What does this study add?
 ► The trial is designed to test the hypothesis that treat-
ment with tocilizumab, an IL-6 receptor antagonist, 
before and during PCI will increase myocardial sal-
vage in patients presenting with acute ST-elevation 
myocardial infarction (STEMI).
How might this impact on clinical practice?
 ► If tocilizumab increases myocardial salvage, IL-6 in-
hibition might be an adjuvant therapeutic target for 
patients with STEMI. Larger endpoint-driven multi-
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Figure 1 The figure shows possible actions for interleukin-6 
(IL-6) and targets for the anti-IL-6 antagonist, tocilizumab in 
the atherothrombotic process. Tocilizumab could (1) reduce 
initiation and progression of the atherosclerotic process, 
(2) stabilise atherosclerotic plaques, (3) inhibit initiation 
and propagation of the thrombus, (4) reduce ischaemia/
reperfusion (I/R) injury, (5) inhibit the maladaptive left 
ventricular remodelling process and (6) prevent development 
of symptomatic heart failure. However, tocilizumab could 
potentially also attenuate infarct healing.
and improve outcomes. The role of inflammation in plaque 
destabilisation and post-MI myocardial remodelling has been 
thoroughly investigated. Several studies have also examined 
the role of IL-6 in these processes. However, at present, there 
are no data on the effect of IL-6 inhibition in patients with 
STEMI.
We recently conducted a double blind, placebo 
controlled trial in 117 patients with non-ST segment 
elevation MI (NSTEMI) who presented at a median 
of 2 days after the onset of chest pain. In this study, a 
single, intravenous dose of the IL-6 receptor antagonist 
tocilizumab reduced C-reactive protein (CRP) levels 
by more than 50% during hospitalisation. Importantly, 
tocilizumab also reduced PCI-related troponin T (TnT) 
levels, suggesting that tocilizumab reduced peripro-
cedural myocardial injury.3 The favourable effects of 
tocilizumab were limited to patients who underwent PCI 
and patients who were randomised within 2 days after 
symptom debut. However, as expected in patients with 
non-STEMI (NSTEMI), the peak TnT plasma concentra-
tions were relatively low (approximately 300 ng/L before 
baseline), and the study was not designed to examine 
the effect on myocardial remodelling or infarct size. The 
beneficial effect of tocilizumab in the NSTEMI popula-
tion may reflect an effect on periprocedural myocardial 
injury (PMI) following PCI, and a stabilising effect on the 
affected coronary plaque, rather than an effect on infarct 
size and myocardial remodelling. Thus, while our recent 
study indicates that IL-6 inhibition has largely favourable 
effects in NSTEMI, it is unknown whether similar, bene-
ficial effects can be obtained in patients with STEMI. 
The pathophysiologies in these patients have similarities, 
but also differences.4 On this background, we wanted to 
investigate the effect of a single fixed dose of tocilizumab 
(280 mg) in patients with acute STEMI. We postulate 
that a single dose of tocilizumab (RoActemra) will have 
favourable effects on myocardial salvage, as assessed by 
cardiac MRI (CMR) and markers of myocardial necrosis, 
without negative consequences for the myocardial repair 
process in these patients.
The ASSessing the effect of Anti-IL-6 treatment in 
Myocardial Infarction (ASSAIL-MI) trial is a randomised, 
controlled, double blind, parallel arm trial designed 
to test the hypothesis that treatment with tocilizumab 
before and during PCI will increase myocardial salvage 
in patients presenting with acute STEMI. Our ambition is 
to improve the prognosis of patients with STEMI, and if 
we fulfil this ambition, our research has the potential to 
change clinical practice.
Acute coronary syndromes (ACS), ischaemia/reperfusion (I/R) 
injury and inflammation
Whereas the abrupt restoration of blood flow by PCI undoubt-
edly has a net beneficial effect, it may also have detrimental 
consequences, including myocardial stunning, ventricular 
arrhythmias and microvascular dysfunction.5 The I/R injury 
may account for as much as 50% of the myocardial damage 
during MI.6 While the myocardial response to the reperfusion 
injury aims to restore homeostasis within the heart through 
repair and adaptive remodelling, a dysregulated process can 
induce maladaptive remodelling and subsequent myocar-
dial failure. An ideal therapeutic approach to MI should (1) 
counteract plaque destabilisation and thrombus formation, 
(2) impair the I/R injury, (3) minimise infarct size and (4) 
inhibit maladaptive remodelling without attenuating the 
repair process. At present, we lack the necessary tools to fully 
achieve these goals.
Inflammation is involved in several aspects of coronary 
artery disease (CAD) and ACS. Plaque destabilisation (ie, 
endothelial erosions and fibrous cap rupture) with subse-
quent thrombus formation and vascular obstruction is the 
principal cause of acute coronary events. Inflammation is 
involved in all these features of ACS.7 8 In addition, different 
cytokines as well as reactive oxygen species (ROS), intracel-
lular calcium overload and myocardial infiltration of leuco-
cytes may contribute to the reperfusion injury occurring 
after the opening of occluded coronary arteries. Enhanced 
oxidative stress activates inflammatory pathways within the 
myocardium, which again enhances ROS production, in a 
vicious cycle after PCI.6 Myocardial inflammation is also a 
major contributor to infarct size through the activation and 
release of matrix degrading enzymes and induction of cardio-
myocyte and fibroblast apoptosis and necrosis. However, 
while the injurious role of inflammation in MI is well estab-
lished, how to modulate the activation of the inflamma-
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Figure 2 Overall study design.
inflammatory responses are harmful and may contribute to 
myocardial damage and increased infarct size, inflammation 
is also prerequisite for tissue repair. This dual role of inflam-
mation following MI represents a therapeutic challenge.
therapeutic intervention during MI
Recently, a great breakthrough on therapeutic approaches 
targeting inflammation in atherosclerotic disorders 
was achieved with the Canakinumab Anti-inflammatory 
Thrombosis Outcomes Study trial.9 In this trial, anti-in-
flammatory therapy with the interleukin-1 beta (IL-1β) 
antibody canakinumab led to a significantly lower rate of 
recurrent cardiovascular events in patients with previous 
MI. However, few studies have explored anti-inflamma-
tory strategies in MI. A randomised trial evaluating IL-1 
receptor (IL-1R) antagonism in NSTEMI showed a signif-
icantly lower level of CRP in the intervention arm, but 
not during the first 2 days after drug administration, and 
without effects on TnT.10 A larger multicentre study on 
the effect of the IL-1R antagonist anakinra in patients 
with STEMI is ongoing.11 In patients with STEMI, pexeli-
zumab (n=960), which inhibits the C5 complement 
protein12 mitigates inflammation. Moreover, whereas 
pexelizumab had no measurable effect on infarct size, it 
showed a significant reduction in mortality. Subsequent 
studies, however, have failed to demonstrate effects on 
clinical outcomes.13 In fact, used adjunctively with fibrino-
lytic agents, pexelizumab did not reduce infarct size, as 
assessed by creatine kinase-myocardial band (MB), or the 
risk of adverse clinical events.14 Recently, Defteros and 
colleagues showed that in patients with STEMI (n=151), 
the antirheumatic drug colchicine could reduce creatine 
kinase-MB, and, in a subgroup of patients, infarct size 
as assessed by CMR.15 Moreover, inclacumab targeting 
P-selectin, an adhesion molecule that facilitates the inter-
action between platelets, endothelial cells and leuco-
cytes, was found to reduce TnI after PCI in patients with 
NSTEMI (n=322).16 More recently, the p38 mitogen-ac-
tivated protein kinase inhibitor losmapimod, known to 
attenuate a range of inflammatory pathways, failed to 
improve outcomes in a relatively large randomised trial 
in patients with NSTEMI (n=3503).17
To date, there are no studies on IL-6 inhibition in 
patients with STEMI. Several drugs (eg, glycoprotein IIb/
IIIa antagonists) attenuate the levels of circulating IL-6 
after ACS and PCI.18 However, there are studies suggesting 
that IL-6 is insufficiently suppressed with contemporary 
therapies. In the Myocardial Ischemia Reduction with 
Acute Cholesterol Lowering study, treatment with ator-
vastatin reduced the level of circulating CRP, but failed 
to reduce IL-6 levels.19 Moreover, numerous studies 
have shown that, despite ‘optimal’ therapy, IL-6 levels 
are higher in patients with ACS than in patients with 
stable coronary disease and healthy control subjects. 
In summary, there seems to be an unfulfilled need for 
treatment targeting IL-6. This unfulfilled need forms the 
scientific background for the ASSAIL-MI trial.
the role of IL-6
IL-6 is a multifunctional cytokine that is produced by a spec-
trum of cell types in the cardiovascular and immune systems 
and can influence the cardiovascular system in several ways 
(figure 1). It has been linked to vascular inflammation and 
myocardial remodelling. IL-6 and its signalling through 
the IL-6-receptor complex contribute to atherosclerotic 
plaque development and plaque destabilisation20 and has 
also been related to the progression of myocardial failure.21 
IL-6 is a pleiotropic cytokine with a wide range of effect on 
immune cells and other cells with relevance for cardiovas-
cular disease.22 IL-6 is the main promoter of acute-phase 
proteins, such as CRP, and the subsequent complement 
activation. It causes the release of prothrombotic mediators 
and activation of matrix metalloproteinases. This result in 
matrix degradation and weakening of the atherosclerotic 
fibrous cap and may also have harmful effects on the repair 
process after MI.
IL-6 plays a significant role in myocardial remodelling 
predisposing to the development of overt heart failure. 
Experimental mice models have shown that enhanced 
IL-6 activation promote myocardial hypertrophy. 
However, deficiency of its receptor induced severe 
cardiac dilation.23 These findings illustrate the balance 
between beneficial and harmful effects of this cytokine 
where too much and too little can both be harmful. Inter-
estingly, in an experimental mice model, Kobara et al 
found that therapy targeting the IL-6 receptor downregu-
lated inflammation and attenuated LV remodelling after 























4 Anstensrud AK, et al. Open Heart 2019;6:e001108. doi:10.1136/openhrt-2019-001108
Figure 3 Study flow chart.
in humans. We have shown that high levels of soluble 
IL-6 receptors (ie, IL-6R and gp130) in the acute phase 
of STEMI are associated with subsequent major cardiac 
adverse events, underscoring the potential importance 
of the IL-6 signalling system in patients with MI.25 To 
conclude, IL-6-related pathways seem to be involved in 
several pathogenic processes during MI, from plaque 
destabilisation and thrombus formation to I/R injury and 
maladaptive myocardial remodelling and our hypothesis 
is that IL-6 inhibition has several beneficial effects in 
STEMI (figure 1).
Known and potential benefits and risks of targeting IL-6 
therapy in StEMI
IL-6 inhibition with a single dose of tocilizumab may 
have several merits. First, in contrast to long-term 
anti-inflammatory therapy in various autoimmune 
disorders, we hypothesise that one dose of tocilizumab 
administered on admission may be sufficient to induce 
beneficial effects on infarct size and myocardial remod-
elling. Accordingly, the patients will not be exposed to 
long-term immunosuppression with its potential harmful 
effects. Second, in contrast to IL-1β, which is an upstream 
inflammatory cytokine, IL-6 is a more downstream medi-
ator. Although the effect of IL-1β inhibition seems at 
least partly to be mediated through reduction of levels 
of IL-6,26 we found only minor alterations in the cytokine 
network during tocilizumab intervention in patients 
with NSTEMI, suggesting a more narrow effect of IL-6 
inhibition.27 We therefore expect that the targeted IL-6 
therapy provided in the ASSAIL-MI trial will to a lesser 
degree interfere with other inflammatory pathways, 
some of which may be of importance for infarct healing. 
Third, to balance the beneficial and harmful effect of 
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box 1 The main inclusion and exclusion criteria
Inclusion criteria
 ► New ST elevation at the J-point in two contiguous leads (cut-points: 
0.2 mV in men and >0.15 mV in women in leads V2–V3 and/or 
>0.1 mV in other leads) in combination with symptoms consistent 
with acute myocardial infarction (MI).
 ► Presentation within 6 hours of chest pain.
 ► Indication for urgent coronary angiography with intent to reperfuse 
presumed occluded vessel.
 ► Age between 18 and 80 years.
 ► Informed consent obtained and documented according to 
International Council for Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH)/Good 
Clinical Practice and national/local regulations.
Exclusion criteria
 ► Non-ST elevation MI (NSTEMI) (non-ST segment elevation in ECG).
 ► Left bundle branch block in ECG.
 ► History of previous MI.
 ► Cardiogenic shock.
 ► Fibrinolytic therapy within 72 hours prior to admission.
 ► Cardiac arrest/ventricular fibrillation.
 ► History of severe renal failure with estimated glomerular filtration 
rate <30 mL/min.
 ► Known, current liver disease.
 ► History of concurrent inflammatory, biliary obstructive or malignant 
disease.
 ► Ongoing infection.
 ► A history of chronic or concurrent infectious disease, including a 
history of HIV, tuberculosis or hepatitis B or C.
 ► Known, uncontrolled lower gastrointestinal (GI) disease such as di-
verticulitis, Crohn’s disease, ulcerative colitis or other symptomatic 
lower GI conditions that could predispose to GI perforations.
 ► Major surgery within 8 weeks prior to or after baseline.
 ► History of central nervous system demyelinating or seizure 
disorders.
 ► History of primary or secondary immunodeficiency.
 ► Treatment with immunosuppressants other than low dose cortico-
steroids (equivalent to 5 mg of prednisone or less) at the time of 
randomisation.
 ► Immunisation with a live/attenuated vaccine within 4 weeks prior 
to baseline.
 ► History of severe allergic or anaphylactic reactions to humanised or 
murine monoclonal antibodies or to tocilizumab.
 ► Pregnancy, possible pregnancy or breast feeding—women of child-
bearing potential or breastfeeding mothers cannot participate. A 
woman is considered of childbearing potential following menarche 
and until becoming postmenopausal unless permanently sterile. 
Permanent sterilisation methods include hysterectomy, bilateral 
salpingectomy and bilateral oophorectomy. A postmenopausal state 
is defined as no menses for 12 months without an alternative med-
ical cause.
 ► Contraindications to cardiac MRI (pacemaker, cardiac resynchro-
nisation therapy, implantable cardioverter defibrillator, certain 
ferromagnetic implants, severe claustrophobia, allergy to contrast 
medium).
 ► Any condition/circumstances believed to interfere with the ability to 
comply with protocol.
 ► Any reason why, in the opinion of the investigator, the patient should 
not participate.
Continued
and fixed dose of tocilizumab (280 mg) that will provide 
complete IL-6 blockade of approximately 2 weeks. 
Notably, in the NSTEMI study, we found no association 
between body mass index and the effect of tocilizumab 
on CRP, suggesting that its effect is influenced by body 
weight to a minor degree only.3 There are several poten-
tial challenges with anti-IL6 inhibition during STEMI. 
We know that tocilizumab is associated with an increased 
risk of infections. However, this risk is probably low after 
a single dose only. In the NSTEMI study, we recorded 
no severe infectious complications in patients receiving 
tocilizumab.3 Tocilizumab induced a significant reduc-
tion in blood levels of neutrophils,3 but based on the 
role of these cells during MI, this could be a beneficial 
rather than a harmful effect.28 As discussed above, there 
is also increased risk of impaired healing after MI during 
IL-6 inhibition, potentially increasing the risk of myocar-
dial rupture and cardiac dilation. However, we consider 
this risk to be small in patients treated within 6 hours of 
symptom onset. Finally, there have been some concern 
about the hyperlipidaemic effects of tocilizumab, but 
hyperlipidaemia was not observed in the NSTEMI trial. 
This may reflect differences in the interaction between 
inflammation and lipid metabolism between patients 
with CAD and patients with autoimmune disorders like 
rheumatoid arthritis, potentially related to the fact that 
nearly all patients with CAD receive statins.29
MEtHodS And AnALySIS
design
The ASSAIL-MI trial is a phase II, double blind, 
randomised, placebo-controlled trial conducted at three 
experienced, high volume PCI centres in Norway. Partic-
ipants are randomised in a 1:1 fashion to receive a single 
intravenous fixed dose of tocilizumab (280 mg) tocili-
zumab or matching placebo prior to PCI. The study is 
designed to show superiority with regard to the primary 
endpoint in patients assigned to active treatment vs 
patients allocated to the placebo arm. The overall study 
design is presented in figure 2 and study procedures in 
figure 3.
Eligibility
The inclusion and exclusion criteria are presented in 
box 1.
Patients with first time STEMI scheduled for acute PCI 
within 6 hours from the onset of chest pain are screened 
for eligibility on admittance at either participating site. 
Informed consent is obtained for all enrolled patients 
aged between 18 and 80, fulfilling ECG criteria for 
STEMI, and accepted for urgent coronary angiography 
with the intention to reperfuse a presumed occluded 
vessel within the given time limit. Haemodynamically 
unstable patients and patients with previous MI or severe 
comorbidities are not included in this trial. Exclusion 
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box 1 Continued
 ► Failure to obtain written, informed consent by patient or next of kin, 
for instance in case of patient death after consent has been pro-
vided in oral.
box 2 Prespecified endpoints in the ASSessing the effect of 
Anti-IL-6 treatment in Myocardial Infarction trial
Primary endpoint
 ► The between-group difference in myocardial salvage index as mea-
sured in the acute phase by cardiac MRI (CMR) with late gadolinium 
enhancement (LGE).
Secondary endpoints
 ► The between-group differences in the area under the curve (AUC) 
for troponin T during index hospitalisation (baseline adjusted).
 ► Final infarct size as measured by CMR 6 months after randomisation.
 ► The between-group difference in the AUC for aspartate aminotrans-
ferase and creatine kinase-myocardial band during index hospital-
isation (baseline adjusted).
 ► The between-group differences in the AUC of C-reactive protein 
during index hospitalisation (baseline adjusted).
 ► The extent of microvascular obstruction as measured by CMR after 
3–7 days.
 ► Left ventricular size as assessed by CMR six6 months after 
randomisation.
 ► Markers of myocardial remodelling as assessed by echocardiography.
 ► Baseline-adjusted N-terminal prohormone of brain natriuretic pep-
tide at 6 months.
 ► Safety and tolerability as assessed by clinical assessment, blood 
samples and imaging.
Explorative endpoints
 ► Additional inflammatory and anti-inflammatory mediators.
 ► Markers of extracellular matrix remodelling (eg, matrix metallopro-
teinases and their endogenous inhibitors).
 ► Lipid parameters (eg, low-density lipoprotein and high-density lipo-
protein cholesterol and triglycerides).
 ► Markers of platelet activation (eg, platelet-derived inflammatory 
markers) and additional prothrombotic and antithrombotic parame-
ters (eg, tissue factor and plasminogen activator inhibitor).
objectives
Primary objective
The primary objective of the ASSAIL-MI trial is to examine 
the effect of tocilizumab on myocardial salvage index as 
measured by CMR with gadolinium late enhancement 
3–7 days after study drug infusion.
Secondary objectives
Secondary objectives are to assess the impact of treat-
ment on: (1) troponin release, (2) final infarct size, (3) 
other biomarkers of myocardial damage (ie, aspartate 
aminotransferase and creatine kinase-MB), (4) CRP levels 
during hospitalisation, (5) markers of left ventricular 
(LV) remodelling and (6) safety and tolerability.
Explorative endpoints
Endpoints that could explain the mechanisms of action 
of tocilizumab in STEMI: (1) additional markers of 
inflammation, (2) markers of extracellular matrix remod-
elling, (3) lipid parameters, (4) markers of platelet acti-
vation and additional prothrombotic and antithrombotic 
parameters. Endpoints are detailed in box 2.
Rationale for study endpoint
Infarct size is a major determinant of prognosis after MI and 
can be accurately measured by gadolinium late enhance-
ment CMR.30 CMR is also the method of choice for the eval-
uation of LV function in this setting. Infarct size is mainly 
determined by two factors: the size of the myocardial terri-
tory supplied by the occluded vessel and the efficacy of the 
therapeutic actions taken to restore normal blood flow 
and minimise myocardial damage. In the present study, we 
will study the effect of tocilizumab on myocardial damage 
during reperfusion. This effect can be evaluated by the 
myocardial salvage index, which is calculated by indexing 
the area of the salvaged myocardium to the area at risk of 
irreversible injury, thus relating the size of the damage to 
the area at risk. The myocardial salvage index has recently 
been used in several large clinical cardioprotection trials 
(CHILL-MI,31 MITOCARE,32 METOCARD-CNIC,33 LIPSIA 
CONDITIONING).34 The area at risk can be quantified 
with early gadolinium enhancement images, applying a 
standard CMR sequence.
In addition to infarct size and the salvage index, CMR 
can assess microvascular obstruction, which is considered a 
marker of severe myocardial damage and poor prognosis.35 
Soluble markers of myocardial damage, in particular TnT 
which is the most established marker for assessment of 
myocardial damage during STEMI, will be an important 
secondary endpoint. Explorative endpoints will elucidate 
possible mechanisms of action of tocilizumab in STEMI.
Statistical considerations
This trial is designed to assess the effect of treatment with 
tocilizumab on myocardial salvage in patients with STEMI. 
In patients with first time, acute anterior wall MI treated 
with PCI within 12 hours of the onset of symptoms, final 
infarct size is typically 20% of total myocardial volume.36 
Studies have shown that an absolute reduction in infarct 
size of approximately 3%–5% of myocardial volume, that 
is, a relative reduction of 14%–25%, given an infarct size 
of 20%, is associated with improved survival and a reduc-
tion in clinical events.37 We therefore consider a decrease 
in (1−the myocardial salvage index) of 20% (equalling 
20% reduction in infarct size) to be clinically relevant. 
With a two-sided α of 0.05 and a power of 90 %, detec-
tion of a 20% between-group difference in (1−myocardial 
salvage index) requires 86 patients in each arm.38
In a recent trial on the effect of IL-6 inhibition in 
patients with NSTEMI, we showed that treatment with 
tocilizumab was associated with reduced PCI-released 
release of TnT.3 In the ASSAIL-MI trial, the baseline-ad-
justed between-group difference in AUC for TnT will be 
an important secondary endpoint. In order to reduce the 
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Table 1 Baseline characteristic of the first 100 patients in 
the ASSessing the effect of Anti-IL-6 study
Demography
Age, years (range) 61.0±8.7 (38–79)
Male gender, n (%) 80 (80.0)
Race/ethnicity, n (%)
  White/Black/Asian 96 (96.0)/0 (0.0)/4 (4.0)
Relationship status, n (%)
  Married/single/widow(er) 73 (73.0)/22 (22.0)/5 (5.0)
Work status, n (%)
  Working/sick leave/pensioner 61 (61.0)/4 (4.0)/34 (34.0)
Cardiovascular risk factors, n (%)
  Current smoker/former smoker 40 (40.0)/26 (26.0)/34 (34.0)
  Hypertension 33 (33.0)
  Diabetes mellitus 7 (7.0)
  Peripheral vascular disease 2 (2.0)
Chest pain to hospital arrival time, hours 
(range)
2.4±1.2 (0.42–6.0)
Concomitant medication, n (%)
  ACE-inhibitor/angiotensin receptor 
blocker
26 (26)
  Aldosterine antagonist 1 (1)
  Anticoagulants 4 (4)
  Antiplatelets 10 (10)
  Beta blocker 7 (7)
  Calcium antagonist 14 (14)
  Diuretics 10 (10)
  Statin 10 (10)
  Other 25 (25)
Clinical characteristics
Blood pressure, mm Hg (range)   
  Systolic 132.3±21.5 (80.0–180.0)
  Diastolic 82.7±16.2 (50.0–121.0)
Heart rate, beats per minute (range) 70.8±16.1 (40.0–125.0)
Body mass index, kg/m2 (range) 27.0 (15.7–39.2)±4.3
Killip classification, n (%)
  I/II/III/IV 95 (95)/4 (4)/0 (0)/0 (0)
New York Heart Association functional status, n (%)
  I/II/III/IV 62 (62)/27 (27)/3 (3)/7 (7)
Data are given as number (percent) or mean±SD (range)
80%, we need approximately 75 patients in each arm.38 
To allow for dropout and to improve the chances of 
obtaining significance for secondary endpoints, we there-
fore aim to include all together 200 patients.
All statistical tests will be performed using a two-sided 
5% level of significance. Continuous efficacy variables will 
be analysed using independent t-tests for comparisons 
between the treatment arms and baseline-adjusted anal-
ysis of covariance (ANCOVA) for difference in changes. 
If necessary, values will be log-transformed to meet the 
assumptions of the tests. All analyses will be analysed 
according to the intention-to-treat principle. Between-
group differences in ordinal categorical variables, such as 
New York Heart Association class, will be analysed using 
ordinal logistic regression, whereas the count variables 
will be assessed by Poisson regression. Demographic, 
efficacy and safety data will be summarised by treatment 
group using means, minimums, medians, maximums, 
IQRs and SD for continuous variables and frequency 
counts and percentages for categorical variables. Per-pro-
tocol analyses will be performed using the same methods 
as for the intention-to-treat analyses.
The between-group difference in the myocardial salvage 
index as measured by CMR 3–7 days after study drug 
infusion will be assessed by an independent Student’s 
t-test according to the intention-to-treat principle, the 
statistical null hypothesis being that the myocardial 
salvage index does not differ between the two treatment 
arms. Secondary analyses will be made according to the 
per-protocol principle. For TnT, the baseline-adjusted 
between-group difference in AUC for TnT will be calcu-
lated by ANCOVA, if necessarily after log transformation. 
The statistical null hypothesis is that the TnT release does 
not differ between patients allocated to tocilizumab and 
patients allocated to placebo.
Safety analyses will include tabulation of the type and 
frequency of adverse events. Any serious adverse events 
will be reported with comprehensive narratives. Any 
value of safety laboratory parameters outside normal 
ranges will be identified.
Study management
A trial steering committee oversees the progress of 
the trial. An independent data monitoring and safety 
committee is responsible for the regular monitoring of 
trial data, and it will give advice on whether the accumu-
lated safety data, together with the results from other 
relevant research, necessitate premature termination of 
the trial.
EtHICS And dISSEMInAtIon
The ASSAIL-MI trial is designed to assess the effect 
of a therapeutic intervention with the aim to improve 
outcome in a population with considerable known 
mortality and morbidity. The trial is conducted according 
to Good Clinical Practice guidelines. Based on previous 
trials and drug pharmacodynamics, we do not expect a 
substantial number of drug-related severe adverse events. 
The trial complies with the Declaration of Helsinki. All 
patients provide written informed consent before enrol-
ment and randomisation.
This study was initiated in February 2017 and is 
currently recruiting patients at all three participating 
sites. As of April 2019, 135 patients have been enrolled. 
Baseline characteristics of the first 100 of these patients 
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We expect patient recruitment to be complete by the 
end of 2019. We expect the trial to be completed and 
results available in 2020.
If positive, this study may be followed by larger multi-
centre studies with clinical endpoints like mortality and 
hospitalisation as primary endpoints. The study has the 
potential to change clinical practice in the management 
of patients with ACS.
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